In the relentless pursuit of early cancer detection, researchers are turning to microfluidic systems to revolutionize the way we identify critical biomarkers. A recent review published in *Nano Select* (translated to English as “Nano Select”) delves into the advancements of microfluidic devices in collecting specific cancer biomarkers, namely exosomes and circulating tumor cells (CTCs). Led by Bahareh Valinezhad Saghezi from the School of Pharmacy at Kermanshah University of Medical Sciences in Iran, this research highlights the potential of microfluidic technologies to transform cancer diagnosis and treatment.
Traditional methods of cancer detection often come with high costs, time-consuming procedures, and labor-intensive processes. Microfluidic devices, however, offer high throughput, low response time, and precise control of liquid flow. These advantages make them a promising tool for early cancer detection and personalized treatment strategies. “Microfluidic-based approaches can efficiently collect and isolate CTCs and extracellular vesicles (EVs), providing critical information about cancer progression and treatment response,” explains Valinezhad Saghezi.
The review emphasizes the importance of integrating point-of-care (POC) diagnostics with microfluidic technologies. This integration could bring these advanced diagnostic tools to the patient’s bedside, making cancer detection more accessible and efficient. “An important step toward leveraging these advances is ensuring portability to the patient’s bedside,” notes Valinezhad Saghezi.
The commercial impacts of this research are significant, particularly in the energy sector. Early and accurate cancer diagnosis can lead to better treatment outcomes, reducing the need for extensive and costly medical interventions. This, in turn, can lower healthcare costs and improve productivity, benefiting both individuals and the economy.
The research also sheds light on the basics of microfluidics and the techniques used in detecting EVs and CTCs. By advancing cancer research through these methods, microfluidic systems could pave the way for more effective and personalized cancer treatments.
As we look to the future, the integration of microfluidic technologies with POC diagnostics holds immense potential. This advancement could revolutionize cancer diagnosis and treatment, making it more efficient, accessible, and personalized. The work of Valinezhad Saghezi and her team, published in *Nano Select*, is a significant step forward in this exciting field.